ArticleCancer cell2021
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02446860 (A Study of Anti-PD1), which is not on this map. Cited by 186 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 2 pooled it
17.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Who cites it
186 citing papers in PubMed, 2 syntheses or guidelines pooled it, 243 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.Frontiers in immunology · 2024Pooled it
- Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.Nature communications · 2026Trial
- Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.Nature communications · 2025Trial
- Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.Nature medicine · 2024Trial
- Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.Nature medicine · 2023Trial
- Predicting PD-L1 + CD8 - status in non-small cell lung cancer tissue from clinical indicators using machine learning.Chinese medical journal · 2026Article
- scXpand: Pan-cancer detection of T cell clonal expansion from single-cell RNA sequencing without paired single-cell TCR sequencing.Cell genomics · 2026Article
- Global research trends in fecal microbiota transplantation combined with immune checkpoint inhibitors for cancer immunotherapy: a bibliometric analysis.Translational cancer research · 2026Article
- Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes.Cell reports · 2026Article
- Oligoprogressive renal cell carcinoma: What is the role of surgery?BJU international · 2026Review
- Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- Immunometabolic Stress and Immune Suppression in Clear-Cell Renal Cell Carcinoma: Perspectives in Therapeutic Strategy.International journal of molecular sciences · 2026Review
- Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.Cell discovery · 2026Article
- Deciphering mitotic catastrophe-associated transcriptomic patterns in renal cell carcinoma: prognostic significance and immunotherapy-related associations.Biology direct · 2026Article
- AQP1 Suppresses Clear Cell Renal Cell Carcinoma via Epigenetic Silencing and TNF-Mediated Apoptosis.International journal of molecular sciences · 2026Article
- Pan-cancer single-cell and spatial transcriptomics analyses delineate response-associated heterogeneity and therapeutic targets of tumor-infiltrating B cells following immune checkpoint blockade.Cancer immunology, immunotherapy : CII · 2026Article
- Investigation of Transcriptome and Kinome in Non Metastatic and Metastatic Renal Clear Cancer Stem Cells and Their Relationship with Gut Microbiota.Molecular biotechnology · 2026Article
126 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
58 authors at 13 institutions in 4 countries.
Lewis AuCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Emine HatipogluRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Marc Robert de MassyCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Kevin LitchfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Gordon BeattieCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Desiree SchnidrigCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Rachael ThompsonRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
Fiona ByrneCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Stuart HorswellDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
Nicos FotiadisCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London SW3 6JJ, UK.
Steve HazellDepartment of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
David NicolDepartment of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Scott T C ShepherdCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Annika FendlerCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Robert MasonRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Lyra Del RosarioRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Kim EdmondsRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Karla LingardRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Sarah SarkerRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Mary MangwendeRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Eleanor CarlyleRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Jan AttigRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
Kroopa JoshiCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Imran UddinCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
Pablo D BeckerCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK.
Mariana Werner SunderlandCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK.
Ayse AkarcaDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Ignazio PuccioDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
William W YangDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Tom LundTranslational Immune Oncology Lab, Centre for Molecular Pathology, The Royal Marsden Hospital, Sutton SM2 5PT, UK.
Kim DhillonDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Marcos Duran VasquezCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Ehsan GhoraniCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Hang XuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Charlotte SpencerCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
José I LópezDepartment of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, 48903 Barakaldo, Bizkaia, Spain.
Anna GreenDepartment of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK.
Ula MahadevaDepartment of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK.
Elaine BorgDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Miriam MitchisonDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Ian ProctorDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Mary FalzonDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Lisa PickeringRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Andrew J S FurnessRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
James L ReadingCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
Roberto SalgadoDivision of Research, Peter MacCallum Cancer Centre, Melbourne VIC 300, Australia; Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Antwerp, Belgium.
Teresa MarafiotiDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6DD, UK; Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK.
PEACE Consortium
George KassiotisRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
Benny ChainDivision of Infection and Immunity, University College London, London WC1E 6BT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
James LarkinRenal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK; University College London Cancer Institute, London WC1E 6DD, UK.
Sergio A QuezadaCancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
Samra TurajlicCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. Electronic address: samra.turajlic@crick.ac.uk.
TRACERx Renal Consortium
Royal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GBUniversity College Hospital · GBCancer Research UK · GBLondon Cancer · GBCRUK Lung Cancer Centre of Excellence · GBBioCruces Health research Institute · ESPeter MacCallum Cancer Centre · AUSt Thomas' Hospital · GBInstitute of Cancer Research · GBRoyal London Hospital · GBRoyal Marsden Hospital · GBUniversity College London · GB
Funding
Cancer Research UK 20764Cancer Research UK 22246Cancer Research UK 24314Cancer Research UK 29911Cancer Research UK C33499/A20265Cancer Research UK C416/A26233Cancer Research UK C7893/A26233Cancer Research UK FC001099Cancer Research UK FC001169Cancer Research UK FC001988Medical Research Council FC001099Medical Research Council FC001169Medical Research Council FC001988Medical Research Council MR/M009033/1Medical Research Council MR/P014712/2Medical Research Council MR/V033077/1Wellcome Trust FC001099Wellcome Trust FC001169Wellcome Trust FC001988
Abstract
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8
Indexed as
Drug Resistance, NeoplasmCarcinoma, Renal CellCD8-Positive T-LymphocytesClinical Trials, Phase II as TopicEndogenous RetrovirusesExome SequencingGene Expression ProfilingGenomicsHumansImmune Checkpoint InhibitorsKidney NeoplasmsNivolumabProspective StudiesReceptors, Antigen, T-CellSequence Analysis, RNASingle-Cell AnalysisImmune Checkpoint InhibitorsNivolumabReceptors, Antigen, T-Cellanti-PD-1autopsyclear cell renal cell carcinomahuman endogenous retrovirusmultiregionnivolumabT cell receptorTCR clonal maintenanceTCR clonal replacement
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02446860ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.